Ignite Creation Date:
2024-05-06 @ 3:58 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04825990
Status:
RECRUITING
Last Update Posted:
2022-04-07
First Post:
2021-03-29
Brief Title:
Pembrolizumab and Olaparib in RecurrentMetastatic Platinum Resistant Nasopharyngeal Cancer
Sponsor:
Gruppo Oncologico del Nord-Ovest
Organization:
Gruppo Oncologico del Nord-Ovest
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-24
Start Date Type:
ACTUAL
Primary Completion Date:
2025-09-24
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-03-24
Completion Date Type:
ESTIMATED
First Submit Date:
2021-03-29
First Submit QC Date:
March 29 2021
Study First Post Date:
2021-04-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-03-29
Last Update Post Date:
2022-04-07
Last Update Post Date Type:
ACTUAL